Rheumatic Diseases
Frailty is increasingly recognized as an important syndrome in rheumatoid arthritis (RA), occurring more frequently and at younger ages than in the general population. In this interview, Editorial Board member Dr Elena Myasoedova explores the importance of frailty in the risk stratification and long-term management of RA, discussing the aims, design, key findings, and clinical implications of a retrospective cohort study investigating the incidence and risk factors for frailty in RA.
As part of our EULAR 2026 coverage, we spoke with Dr Vinod Ravindran about his key takeaways from this year's congress in London. In this Q&A, he discusses advances in reproductive rheumatology and pregnancy care, the importance of multidisciplinary management, ongoing challenges in access and awareness, and the value of international collaboration in improving outcomes for women with rheumatic diseases.
[touchplayvideo video_id="92ib4mteeq"] The European Alliance of Associations for Rheumatology (EULAR) Congress 2026, held in London, UK, from 3–6 June 2026, brought together rheumatology experts from around the world to share the latest advances in research and clinical care. In ...
Digital health encompasses technologies such as mobile apps, telemedicine, wearables, software and artificial intelligence (AI) that enhance remote, efficient healthcare delivery.1,2 In rheumatic and musculoskeletal diseases (RMDs), these tools address the need for continuous monitoring, early intervention and patient engagement.3,4 ...
Autoimmune rheumatic diseases (AIRDs) predominantly affect women during their reproductive years and are associated with increased risks of infertility and adverse pregnancy outcomes (APOs). These diseases, such as systemic lupus erythematosus (SLE), antiphospholipid antibody syndrome (APS) and rheumatoid arthritis (RA), ...
Polymyalgia rheumatica (PMR) is an inflammatory condition that is typically managed with glucocorticoids, but long-term treatment can be associated with significant adverse effects, underscoring the need for steroid-sparing therapies. The phase 3 REPLENISH trial investigated the efficacy and safety of secukinumab, an IL-17A inhibitor, in patients with PMR. In this interview, conducted at EULAR 2026, Dr Christian Dejaco (Hospital of Brunico, Brunico, Italy) discusses the rationale for targeting IL-17A, reviews the trial’s key findings, and considers their potential implications for clinical practice.
Meet the immunologists redefining the future of practice, research, and technology! The touchIMMUNOLOGY Future Leaders 2026 have been nominated by the immunology community to recognize the rising stars shaping the future of research and clinical care. These clinicians, researchers and innovators are driving progress across the specialty — from advancing clinical practice to challenging convention and improving patient outcomes.
In this Q&A, touchIMMUNOLOGY Future Leader Dr Pérez Vinueza reflects on what first drew her to rheumatology, the mentors who shaped her path in the field, and the current innovations in rheumatology that excite her most.
In this Q&A, touchIMMUNOLOGY Future Leader Dr Talari reflects on what inspired her to pursue a career in rheumatology, how she balances clinical practice, research, and personal development, and the current innovations in systemic lupus erythematosus that excite her most.
We are delighted to announce that Professor Michael T. Nurmohamed, MD PhD, has joined the Editorial Board of touchREVIEWS in RMD. A distinguished clinician, researcher and leader in the field of inflammatory rheumatic diseases, Professor Nurmohamed brings a wealth of expertise spanning cardiovascular involvement in rheumatology, epidemiology and clinical guideline development.
Dear readers, It is a great pleasure to take on the role of Editor-in-Chief of touchREVIEWS in RMD, and I am grateful for the opportunity to introduce myself and to share my vision for the journal. I am a Professor ...
The landscape of rheumatic and musculoskeletal disease research continues to evolve at pace, driven by scientific innovation, interdisciplinary collaboration and an increasing appreciation of the heterogeneity and complexity of the conditions we treat. As we welcome readers to touchREVIEWS in ...
As the field of immunology continues to evolve, staying ahead of the curve has never been more critical. As we welcome the new year, we asked our touchIMMUNOLOGY 2025 Future Leaders to share the developments they believe will shape the future of the field. Here, they highlight five emerging areas poised to influence clinical practice—not only in the year ahead, but for years to come.
As 2025 draws to a close, we’re celebrating another remarkable year of growth, collaboration and innovation at touchIMMUNOLOGY. From thought-provoking expert interviews and peer-reviewed research to dynamic conference coverage and an expanding portfolio of medical education, this year has been defined by meaningful conversations and impactful learning. We’ve had the privilege of engaging with leading clinicians, researchers and partner societies across the globe - bringing together diverse voices to support the immunology community with timely, accessible and authoritative content. As we reflect on the past 12 months, we’re proud to highlight the moments, milestones and stories that shaped our year. Here are just some of the standout highlights from 2025.
In 2025, major advances have taken place across the field of immunology, from precision immunomodulation to cell, gene and AI-driven therapies that are reshaping clinical practice. We asked five members of the 2025 touchIMMUNOLOGY Future Leaders to highlight the developments they believe have been most impactful this year.
In this year-end review, we are pleased to share personal highlights from members of the touchIMMUNOLOGY Expert Faculty, whose perspectives offer a window into the innovations that have most influenced clinical practice and research over the past 12 months. Their reflections capture not only the momentum of 2025, but also the promise of what lies ahead as the field continues to evolve.
The importance of multi-disciplinary clinics for the assessment of patients with interstitial lung disease (ILD) is well established, and these are usually led by chest physicians.1 The role of rheumatologists in such a setting has evolved more recently.2 The main ...
The 2025 ACR Convergence brought together leading clinicians, researchers, and allied health professionals to explore the latest advances in rheumatology. From cutting-edge therapies and diagnostics to evolving approaches in patient care, the meeting highlighted the innovations and collaborations shaping the future of the field.
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
